Q1 2016 13F Holders as of 31 Mar 2016
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
104,661,494
-
Number of holders
-
83
-
Total 13F shares, excl. options
-
27,202,736
-
Shares change
-
+16,626
-
Total reported value, excl. options
-
$474,936,380
-
Value change
-
-$25,989,904
-
Put/Call ratio
-
1.83%
-
Number of buys
-
47
-
Number of sells
-
-43
-
Price
-
$17.46
Significant Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q1 2016
110 filings reported holding RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q1 2016.
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) has 83 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 27,202,736 shares
of 104,661,494 outstanding shares and own 25.99% of the company stock.
Largest 10 shareholders include Essex Woodlands Health Ventures, Inc. (4,592,047 shares), FRANKLIN RESOURCES INC (3,329,070 shares), NQ HCIF GP, Ltd. (3,096,650 shares), JPMORGAN CHASE & CO (3,028,574 shares), Bank of New York Mellon Corp (1,966,165 shares), WELLINGTON MANAGEMENT GROUP LLP (1,651,426 shares), Polar Capital LLP (1,183,631 shares), BlackRock Fund Advisors (1,150,499 shares), Arrowpoint Asset Management, LLC (1,134,796 shares), and VANGUARD GROUP INC (704,340 shares).
This table shows the top 83 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.